Severe Lower Pulmonary Parenchymal & Obstructive Infections

Acute Viral Bronchiolitis

Lower Respiratory Small Airway Inflammatory Disease

Primary risk age: Infants under 2 years (Peak window: 2 to 6 months)

Urgency: Severe
Typical age: Infants under 2 years (Peak window: 2 to 6 months)
Body system: Respiratory System

Typical course: Acute phase lasts 3 to 5 days; total airway clearance and wheeze resolution may take up to 14 to 21 days.

Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13

1. Summary & Pathophysiology

Lower Respiratory Small Airway Inflammatory Disease

Pathophysiology (Development Path)

The virus infects terminal bronchiolar epithelial cells, causing direct cellular necrosis and triggering an intense inflammatory response. Edema, increased mucus production, and accumulated cellular debris cause widespread obstruction of the tiny infant airways. This leads to air trapping, atelectasis, and ventilation-perfusion mismatch.

Primary Causes & Etiology

Respiratory Syncytial Virus (RSV) accounts for over 70% of cases. Human Metapneumovirus and Rhinovirus are common secondary causes.

2. Symptom Continuum

Early Onset Signs
Serous rhinorrhea, sneezing, poor feeding due to nasal occlusion, and a mild low-grade fever around 38°C.
Progressive Phase
Paroxysmal wheezing, dry hacking cough, tachypnea (respiratory rate exceeding 50–60 breaths/minute), and noticeable intercostal wall tugging.
Severe Indicators
Sustained grunting sounds on expiration, deep substernal recessions, periodic apnea episodes exceeding 15 seconds, listlessness, and peripheral oxygen saturation dropping below 90% on room air.

3. Clinical Verification

Clinical examination including pulmonary auscultation. Nasopharyngeal swabs can confirm RSV via enzyme immunoassay or PCR techniques if epidemiologically indicated.

4. Care & Elements Plan

Primary Care Treatment Plan

Supportive hydration and oxygenation framework. Clear upper airway secretions with regular saline suctioning. Administer humidified oxygen if saturation parameters fall.

Home Support Elements

Frequent small-volume feedings to minimize abdominal splinting and support hydration. Regular use of soft bulb suctioning to clear the nasal passages.

Generic Active Ingredients (No Brands)

Hypertonic saline (3% nebulized fluid to hydrate secretions)
Oxygen therapy (delivered via high-flow nasal cannula if respiratory failure threatens). Systemic bronchodilators and steroids are not recommended for typical cases.

Lists active elements only. Never administer self-designed therapies.

5. Doctor Critical Lines

Critical Thresholds: When to See a Doctor

Seek medical evaluation if the infant refuses hydration, shows respiratory rates over 60 breaths/minute, exhibits nostril flaring, or experiences periods of apnea.

6. Vaccine & Prevention

Routine Prophylaxis (Prevention)

Strict hand hygiene and sanitizing surfaces. Palivizumab prophylaxis is recommended for high-risk infants, such as those born prematurely or with congenital heart disease.

Immunization Context

Palivizumab monoclonal antibody injections given monthly during RSV season for high-risk infant cohorts.

7. Timelines & Outlook

Active Timeline

Acute phase lasts 3 to 5 days; total airway clearance and wheeze resolution may take up to 14 to 21 days.

Expected Prognosis

Good for healthy infants, though symptoms can be distressing. Airway hyperreactivity may persist for weeks.

Potential Untreated Complications

Severe dehydration, respiratory failure requiring mechanical ventilation, and secondary bacterial pneumonia.

Severe

Pediatric Asthma

Chronic Reversible Inflammatory Airway Hyperreactivity

Toddlerhood through Adolescence (Onset typically before 5 years)

Mild

Acute Bronchitis

Acute Inflammatory Bronchial Airway Disease

Preschool and School-age Children